Advertisement

A Structure–Activity Relationship Study of Naphthoquinone Derivatives as Antitubercular Agents Using Molecular Modeling Techniques

  • Mukesh C. SharmaEmail author
Original Research Article

Abstract

Tuberculosis (TB) is one of the major causes of death worldwide. Mycobacterium tuberculosis, the leading causative agent of TB, is responsible for the morbidity and mortality of a large population worldwide. In view of above and as a part of our effort to develop new and potent anti-TB agents, a series of substituted naphthoquinone derivatives were subjected to molecular modeling using various feature selection methods. The statistically significant best 2D-QSAR model having correlation coefficient \(r^{2} = 0.8643\) and cross-validated squared correlation coefficient \(q^{2}= 0.7138\) with external predictive ability of \(\hbox {pred}{\_}r^{2} = 0.7420\) was developed by SA-PLS, and group-based QSAR model having \(r^{2} = 0.7964\) and \(q^{2} = 0.7550\) with \(\hbox {pred}{\_}r^{2} = 0.7293\) was developed by SA-PLS. Further analysis using three-dimensional QSAR technique identifies a suitable model obtained by SA-partial least square method leading to antitubercular activity prediction. k-nearest neighbor molecular field analysis was used to construct the best 3D-QSAR model using SA-PLS method, showing good correlative and predictive capabilities in terms of \(q^{2}=0.7863\) and \(\hbox {pred}{\_}r^{2} = 0.7396\). The pharmacophore analysis results obtained from this study show that the distance between the aromatic/hydrophobic and the naphthoquinone moiety sites to the aliphatic and acceptor groups should be connected with almost the same distance for significant antitubercular activity. The information rendered by QSAR models may lead to a better understanding of structural requirements of antitubercular activity and also can help in the design of novel potent antitubercular activity.

Keywords

Naphthoquinone Mycobacterium tuberculosis QSAR k-nearest neighbor PLS Antitubercular agents 

Notes

Acknowledgments

The author are thankful to VLife Sciences Technologies Private Limited, 1 Akshay, 50 Anand Park, Aundh, Pune, India, for providing trial version MDS 3.5 software.

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    World Health Organization (WHO) (2003) WHO annual report on global TB control summary. Wkly Epidemiol Rec 78:121–128Google Scholar
  2. 2.
    Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC (1999) Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282(7):677–686CrossRefGoogle Scholar
  3. 3.
    Williams BG, Dye C (2003) Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 301:1535–1537CrossRefGoogle Scholar
  4. 4.
    Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC et al (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Med 163:1009–1021Google Scholar
  5. 5.
    Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J (1995) Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 151:129–135CrossRefGoogle Scholar
  6. 6.
    Janin YL (2007) Antituberculosis drugs: ten years of research. Bioorg Med Chem 15:2479–2513CrossRefGoogle Scholar
  7. 7.
    Cegielski JP, Chin DP, Espinal MA, Frieden TR, Rodriquez Cruz R, Talbot EA et al (2002) The global tuberculosissituation. Progress and problems in the 20th century, prospects for the 21st century. Infect Dis Clin North Am 161:1–58CrossRefGoogle Scholar
  8. 8.
    Spigelman MK (2007) New tuberculosis therapeutics: a growing pipeline. J Infect Dis 196:828–834CrossRefGoogle Scholar
  9. 9.
    Al-Deeb AO, Alafeefy AM (2008) Synthesis of some new 3H-quinazolin-4-one derivatives as potential antitubercular agents. Worl Appl Sci J 5(1):94–99Google Scholar
  10. 10.
    Islam M, Siddiqui AA, Rajesh R (2008) Synthesis, antitubercular, antifungal and antibacterial activities of 6-substituted phenyl-2-(3’-substituted phenyl pyridazin-6’-yl)-2,3,4,5-tetrahydropyridazin-3-one. Acta Pol Pharm 65(3):353–362PubMedGoogle Scholar
  11. 11.
    Trivedi AR, Siddiqui AB, Shah VH (2008) design, synthesis, characterization and antitubercular activity of some 2-heterocycle-substituted phenothiazines. Arkivoc 2:210–217Google Scholar
  12. 12.
    Osman SAA, Abdalla AA (1983) Synthesis of sulfanilamide naphthoquinones as potential antituberculous agents. J Pharm Sci 72:68–71CrossRefGoogle Scholar
  13. 13.
    Roshdi IM, Ibrahim ESA, Habib NS (1976) Synthesis of 1,4-naphthoquinones-4-aryl(aroyl) hydrazones of potential antimicrobial activity. Pharmazie 31:856–859Google Scholar
  14. 14.
    Bullock FJ, Tweedie JF, Mcritchie DD, Tucker MA (1970) Antiprotozoal quinines. II. Synthesis of 4-amino-1,2-naphthoquinones and related compounds as potential antimalarials. J Med Chem 13:97–103CrossRefGoogle Scholar
  15. 15.
    Yardley V, Snowdon D, Croft S, Hazar B (1996) In vitro activity of diospyrin and derivatives against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. Phytother Res 10:559–562CrossRefGoogle Scholar
  16. 16.
    Brinfworth RI, Fairlie DP (1995) Hydroxyquinones are competitive non-peptide inhibitors of HIV-1 proteinase. Biochim Biophys Acta 1253:5–8CrossRefGoogle Scholar
  17. 17.
    Chemin LS, Buisine E, Yardely V, Kohler S, Debreu MA, Landry V, Sergheraert C et al (2001) 2- and 3-Substituted 1,4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from Trypanosoma cruzi: synthesis and correlation between redox cycling activities and in vitro cytotoxicity. J Med Chem 44:548–565CrossRefGoogle Scholar
  18. 18.
    Hazar B, Sur P, Roy DK, Sur B, Banerjee A (1984) Biological activity of diospyrin towards Ehrlich ascites carcinoma in Swiss A mice. Planta Med 51:295–297CrossRefGoogle Scholar
  19. 19.
    Perry NB, Blunt JW (1991) Cytotoxic and antifungal 1,4-naphthoquinone and related compounds from a New Zealand brown algae, Landsburgia quercifolia. J Nat Prod 54:978–985CrossRefGoogle Scholar
  20. 20.
    Martin YC (1978) Quantitative drug design. Marcel Dekker, New YorkGoogle Scholar
  21. 21.
    Ajmani S, Jadhav K, Kulkarni SA (2006) Three-dimensional QSAR using the k-Nearest Neighbor method and its interpretation. J Chem Inf Model 46:24–31CrossRefGoogle Scholar
  22. 22.
    Cramer RD, Patterson DE, Bunce JD (1988) Comparative molecular field analysis (CoMFA) 1 effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959–5967CrossRefGoogle Scholar
  23. 23.
    Ghosh P, Bagchi MC (2011) Anti-tubercular drug designing by structure based screening of combinatorial libraries. J Mol Model 17:1607–1620CrossRefGoogle Scholar
  24. 24.
    Ghosh P, Bagchi MC (2009) Comparative QSAR studies of nitrofuranyl amide derivatives using theoretical structural properties. Mol Simul 35:1185–1200CrossRefGoogle Scholar
  25. 25.
    Puratchikody A, Natarajan RL, Jayapal M, Doble M (2011) Synthesis, in vitro antitubercular activity and 3D-QSAR of novel quinoxaline derivatives. Chem Biol Drug Des 78:988–998CrossRefGoogle Scholar
  26. 26.
    Prajapati K, Singh S, Pathak AK, Mehta P (2011) QSAR analysis on some 8-methoxy quinoline derivatives as \(\text{ H37R }_{V}\) (MTB) inhibitors. Int J Chem Tech Res 1:408–422Google Scholar
  27. 27.
    Sharma R, Panigrahi D, Mishra GP (2012) QSAR studies of 7-methyljuglone derivatives as antitubercular agents. Med Chem Res 21:2006–2011CrossRefGoogle Scholar
  28. 28.
    Sharma MC, Sharma S (2011) 2D QSAR Study of 7-methyljuglone derivatives: an approach to design anti tubercular agents. J Pharm Toxicol 6:493–504CrossRefGoogle Scholar
  29. 29.
    VLife MDS 3.5 (2008) Molecular Design Suite, Vlife Sciences Technologies Pvt. Ltd., Pune, IndiaGoogle Scholar
  30. 30.
    Mahapatra A, Fourie PB, Hamilton CJ, Meyer JJM, Houghton P, Lall N (2007) Activity of 7-methyljuglone derivatives against Mycobacterium tuberculosis and as subversive substrates for mycothiol disulfide reductase. Bioorg Med Chem 15:7638–7646CrossRefGoogle Scholar
  31. 31.
    Casewit CJ, Colwell KS, Rappe AK (1992) Application of a universal force field to organic molecules. J Am Chem Soc 114(25):10035–10046CrossRefGoogle Scholar
  32. 32.
    Rappe AK, Casewit CJ, Colwell KS, Goddard WA III, Skiff WM (1992) UFF, a full periodic table force field for molecular mechanics and molecular dynamics simulations. J Am Chem Soc 114(25):10024–10035CrossRefGoogle Scholar
  33. 33.
    Baumann K (2002) An alignment-independent versatile structure descriptor for QSAR and QSPR based on the distribution of molecular features. J Chem Inform Comput Sci 42(1):26–35Google Scholar
  34. 34.
    Golbraikh A, Tropsha A (2002) Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection. J Comp Aided Mole Des 16:357–369CrossRefGoogle Scholar
  35. 35.
    Ajmani S, Kulkarni SA (2012) Application of GQSAR for scaffold hopping and lead optimization in multitarget inhibitors. Mol Inform 31:473–490CrossRefGoogle Scholar
  36. 36.
    Clark M, Cramer RD III, Van ON (1989) Validation of the general purpose tripos 5.2 force field. J Comput Chem 10:982–1012CrossRefGoogle Scholar
  37. 37.
    Gasteiger J, Marsili M (1980) Iterative partial equalization of orbital electronegativity–a rapid access to atomic charges. Tetrahedron 36:3219–3228CrossRefGoogle Scholar
  38. 38.
    Darlington RB (1990) Regression and linear models. McGraw-Hill, New YorkGoogle Scholar
  39. 39.
    Guyon I, Elisseeff A (2003) An introduction to variable and feature selection. J Mach Learn Res 3:1157–1182Google Scholar
  40. 40.
    Zheng W, Tropsha A (2000) Novel variable selection quantitative structure-property relationship approach based on the k-nearest neighbor principle. J Chem Inf Comput Sci 40:185–194CrossRefGoogle Scholar

Copyright information

© International Association of Scientists in the Interdisciplinary Areas and Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Drug Research Laboratory, School of PharmacyDevi Ahilya UniversityIndoreIndia

Personalised recommendations